Losartan protects liver against ischaemia/reperfusion injury through PPAR-γ activation and receptor for advanced glycation end-products down-regulation.
about
Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinomaRole of receptor for advanced glycation end products (RAGE) in liver diseaseMolecular pathways in protecting the liver from ischaemia/reperfusion injury: a 2015 updateTelmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARγ and the Akt/GSK-3β pathway.Biomarkers distinguish apoptotic and necrotic cell death during hepatic ischemia/reperfusion injury in mice.Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient miceLosartan activates sirtuin 1 in rat reduced-size orthotopic liver transplantation.Sirtuin 2 aggravates postischemic liver injury by deacetylating mitogen-activated protein kinase phosphatase-1.Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activationInvestigation of phosphoproteome in RAGE signaling.Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.Protective role of silent information regulator 1 against hepatic ischemia: effects on oxidative stress injury, inflammatory response, and MAPKs.Liver regeneration - mechanisms and models to clinical application.Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease.AT1 receptor antagonist induces thermogenic beige adipocytes in the inguinal white adipose tissue of obese mice.Regression of experimental endometriotic implants in a rat model with the angiotensin II receptor blocker losartan.The Coming of Age of the Angiotensin Hypothesis in Alzheimer's Disease: Progress Toward Disease Prevention and Treatment?Novel Targets for Treating Ischemia-Reperfusion Injury in the Liver.
P2860
Q26781477-9310BF8E-2B1D-46FA-939A-826242059800Q27010462-D5939469-0EFE-4452-810D-64BBA35F380DQ28262451-DCC928CB-A929-434F-95B1-8F99119A0C85Q33861931-89D4FC42-C7E2-4D81-B448-7DA544CEA2C1Q34422178-4ECF583F-F45E-4CAE-911C-8269E48A6B27Q34997831-98452D66-5F14-494E-B240-8FF678541AF9Q35843026-BE3658F4-F607-4260-897C-57AA9852E01FQ37561307-DBBC54AD-6B83-4F11-9653-7E8B88AE5A4AQ37631143-541D9203-F36E-45E8-8C6D-39DDC0E99062Q38260264-B5E0B7BA-12BD-4E3C-AF5E-A6F202DFD561Q38781028-726D7577-313D-4583-80F7-9B87CD888B8BQ38795156-4B53D39E-1AD7-4BC1-938D-94ADD57DA2DAQ38879963-FB1AB545-FAB9-46B4-8AE9-5F2EACF76FD5Q40402609-A3C8BB1D-BDE0-47EC-BA62-8CC49135C363Q48051040-0721F043-79CB-4480-AD5F-5CEA2B333AEAQ51107745-333E873A-7225-4E3B-83CB-F75970006D64Q52347539-454F7913-5860-44F3-A25F-A7FD7E990BC0Q52559151-173EEB89-775E-4847-80AB-9A59645ABA74
P2860
Losartan protects liver against ischaemia/reperfusion injury through PPAR-γ activation and receptor for advanced glycation end-products down-regulation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Losartan protects liver agains ...... end-products down-regulation.
@en
Losartan protects liver agains ...... end-products down-regulation.
@nl
type
label
Losartan protects liver agains ...... end-products down-regulation.
@en
Losartan protects liver agains ...... end-products down-regulation.
@nl
prefLabel
Losartan protects liver agains ...... end-products down-regulation.
@en
Losartan protects liver agains ...... end-products down-regulation.
@nl
P2093
P2860
P356
P1476
Losartan protects liver agains ...... end-products down-regulation.
@en
P2093
Eun-Ji Koh
Seong-Jin Yoon
Sun-Mee Lee
P2860
P304
P356
10.1111/BPH.12229
P407
P577
2013-07-01T00:00:00Z